Stacey counsels on regulatory matters impacting private funds and their managers. She advises registered and exempt investment advisers of all sizes on legal and compliance issues that arise from federal securities laws, especially in the face of newly developing trends and regulations.
Cooley advised Chemistry, an early-stage venture firm that leads investments in standout software companies at the Seed and Series A stages, on its $350 million debut fund, Chemistry Fund 1.
Cooley advised 20VC, a UK-based firm focused on the intersection of venture capital and media, on the closing of its $400 million third venture capital fund.
Cooley advised Acrew Capital, an early-stage VC firm, on its raise of $700 million in new capital across a family of funds to continue supporting world-class founders in three key sectors: data and security, fintech, and health.
PruVen Capital Closes Oversubscribed $378.5 Million Fund II
September 3, 2024
Cooley advised PruVen Capital, an independent venture capital firm whose investors are exclusively global leaders in financial services and insurance, on the close of its oversubscribed $378.5 million second fund.
2024 07 02 Industry Ventures Raises Oversubscribed 900 Million Hybrid Early-Stage Fund
July 2, 2024
Cooley advised Industry Ventures, a top investment firm focusing on venture capital, on its $900 million seventh hybrid fund investing in emerging seed and early-stage funds through primary and early secondary limited partnership interests and direct investments.
